Biosimilar Trastuzumab Effective in Triplet Regimen for Gastric Cancer
A biosimilar version of Herceptin taken in combination with chemo and the immune-boosting drug Keytruda reduced tumor size in a... Read More
Our Impact
Gastric Cancer Foundation improves the lives of people affected by gastric (stomach) cancer by supporting patient education initiatives and innovative research studies to improve treatments and ultimately, find a cure.
Support Research for a Cure
Every contribution to Gastric Cancer Foundation makes a difference. Honor a loved one, make a tribute to someone’s memory, honor a happy occasion by making a meaningful donation.
-
Drug-Drug Interactions to Avoid in Patients With GI Cancer
People with HER2-positive gastric cancer should not take proton pump inhibitors for heartburn while they are undergoing treatment, recent studies... Read More
FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers
Adding Herceptin to chemotherapy in gastric cancer patients with ERBB2-negative tumors improved the response rate from 61% to 85% in... Read More
The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target
Tumor-associated macrophages represent an exciting new target in the development of treatments for gastric cancer.-
RemeGen Co., Ltd. Announced New RC48-ADC Data in Patients with Advanced Gastric Cancer at ASCO
RemeGen announced a 24% response rate in a clinical trial of its antibody drug conjugate RC48 in patients with HER-2... Read More 
MacroGenics Announces Margetuximab Granted Orphan Drug Designation in the U.S. for Gastric Cancer
MacroGenics received orphan drug designation from the FDA for its investigational gastric cancer drug margetuximab.
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
Gastric cancer patients treated with Enhertu in a recent study had favorable response rates, survival and duration of response as... Read More
Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer
A recent trial of a combination of Stivarga and Opdivo showed better activity than either drug alone in patients with... Read More
FDA Grants Full Approval of Deciphera Pharmaceuticals’ QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
The FDA approved Deciphera Pharmaceuticals’ Quinlock (ripretinib) for the treatment of advanced gastrointestinal stromal tumors.
ctDNA Identifies Acquired Resistance Mechanisms to Savolitinib in MET+ Gastric Cancer
An early trial of AstraZeneca’s MET inhibitor savolitinib in gastric cancer revealed mutations that confer drug resistance.
GCF-AGA Grant Awards Newest Research Scholar: Samuel J Klempner, MD
Samuel J. Klempner, M.D., was completing his fellowship at Beth Israel Deaconess Medical Center in Boston when he first became... Read More
Enhertu granted Orphan Drug Designation in the US for gastric cancer
AstraZeneca and Daiichi Sankyo won breakthrough designation and orphan drug designation from the FDA for Enhertu in treating HER2-positive gastric... Read More-
ASCO: In stomach cancer, AstraZeneca and Daiichi’s Enhertu goes where Roche’s Kadcyla couldn’t
In a pivotal study, patients taking Enhertu from AstraZeneca and Daiichi Sankyo saw their tumors shrink and were still alive... Read More 
Older versus younger adults with gastric cancer receiving perioperative treatment: Results from the CRITICS trial
A new study finds that compliance to treatments prescribed after surgery is worse in older adults being treated for gastric... Read More
Hispanic/Latino gastric adenocarcinoma patients have distinct molecular profiles including a high rate of germline CDH1 mutations
Gene sequencing revealed a high rate of mutations that raise the risk of gastric cancer among people of hispanic origins,... Read More
Oesophageal and proximal gastric adenocarcinomas are rare after detection of Helicobacter pylori infection
A study of more than 36,000 people with H. pylori raises questions about the long-held belief that eradicating the infection... Read More
Low-Dose Aspirin Might Lower Odds for Digestive Cancers
Low-dose aspirin may reduce the risk of digestive tract cancers, including gastric cancer, according to European researchers who analyzed 113... Read More
YAP1 mediates gastric adenocarcinoma peritoneal metastases that are attenuated by YAP1 inhibition
A new study led by GCF grant recipient Jaffer Ajani of MD Anderson found a link between the cancer-associated gene... Read More
Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma
Five Prime Therapeutics’ investigational drug bemarituzumab showed promising efficacy in the late-line treatment of gastroesophageal junction adenocarcinoma.-
GCF Grant Recipient, Jaffer Ajani, MD, Speaks on the Rapidly Evolving Science of Gastric Cancer
Check out GCF grant recipient Jaffer Ajani of MD Anderson in this video presentation on the rapidly evolving science of... Read More
Monthly Newsletter
We’ll deliver our monthly newsletter to your Inbox with Foundation updates, news about cutting edge research and trends in the field, and how to make a difference.